An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- University of Alabama at Birmingham
- Study ID
- NCT05124080
- Phase
- EARLY_PHASE1
- Status
- Completed
Conditions
- Nail Psoriasis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- Deucravacitinib — DRUGAll participants will receive 6 mg of Deucravacitinib daily.
Study Details
. An open label proof of concept study will be conducted to assess the efficacy and safety of deucravactinib for treatment of nail psoriasis. Twenty adult patients with nail psorasis and skin disease qualifying for a systemic agent per investigator will be treated with deucravacitinib 6 mg daily. Subjects will be assessed for a total of 48 weeks. Psoriasis assessments such as the modified Nail Psoriasis Severity Index will be conducted. Photos will be used to document nail involvement. Descriptive statistical analysis will be conducted at the conclusion of the study.
Key Dates
- Start date
- Mar 1, 2024
- Status verified
- Dec 2025
- Primary completion
- Dec 1, 2025
- Completion
- Dec 1, 2025
Study Design
- Enrollment
- 1 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Deucravacitinib 6 mg DailyAll participants will receive 6 mg of deucravacitinib daily.
Primary Outcome Measure
Change in the modified Nail Psoriasis Severity Index (mNAPSI) compared to baseline [ Time Frame: baseline to week 24 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama at Birmingham - Department of Dermatology | Birmingham | Alabama | 35233 | - |